预约演示

AACR: Synthekine hopes new IL-2 will be the high-alpha in a beta class

2024-04-10

AACR会议

Responding to some of the challenges of its peers, Synthekine built a molecule called an IL-2 alpha/beta, dubbed STK-012.

IL-2 medicines have shown the ability to kill tumorSynthekinenately, they aren’t very speIL-2 alpha/betacome to bSTK-012iated with toxicities. Synthekine is hoping to avoid activating lymphocytes such as natural killer cells that can cause these issues, creating a safer and more tolerable medicine.

IL-2’s what early data from a phase 1a/1b triatumorsTK-012 seem to show, CEO Debanjan Ray told Fierce Biotech on the sidelines of the American Association for Cancer Research annual meeting Monday.

The results are very early, with just a handful of STK-012 responses. And Ray is well aware of the struggles of other IL-2s in the clinic—see Sanofi’s many chaCancers with the target.

Responding to some of the hurdles faced by his peers, Ray said that with STK-012, Synthekine has built a molecule called an IL-2 alpha/beta thSanofimeant to stimulate CD25+ antigen-activated T cells but avoid the same reaction with the NK cells that can drive toxicity in IL-2 meds.

The early-stage trial tested the med in 47 patients with advanced solid tSTK-012ncluding non-small cell lung cancer, renal cIL-2 alpha/betand ovarian cancer. Most of tCD25atients had three or more lines of therapy prior to entering the trial, which tested seven dose levelIL-2 two dosing schedules.

Of the 40 evaluable patients, three had a partial responsadvanced solid tumorsnd 12 had snon-small cell lung cancerofrenal cell carcinoma not ovarian cancerponded to immune checkpoint inhibitors and were minimally pretreated, three had a best overall response of partial response and six had stable disease.

“The promise of IL-2 in the treatment of solid tumors has yet to be realized as IL-2 analogues developed to date have had limited efficacy and an unacceptable toxicitimmune checkpoint inhibitors immune checkpoint inhibitors immune checkpoint inhibitorsi, M.D., Synthekine’s chief medical officer, in a Tuesday statement.

The therapy was IL-2ciated with favorablesolid tumorsrmacokinetics and pharmacodIL-2 analoguesa profile that was different from aldesleukin and non-alpha IL-2 analogues. The early data suggest that STK-0Synthekinective for T cells that express CD25. Ray also noted that the response was durable in multiple subjects, with some continuing to benefit for as much as a year after the data cutoff.

Synthekine’s presentation included one patient case study of a 72-year-old female who had stage 4 clear cell renal cell carcinomaldesleukinrevionon-alpha IL-2 analogues of therapy. The patient had “STK-012able lung metastases and a large primarCD25nal mass.” At Week 12, the photos show a reduction in tumors.

“You don't need to be a radiologist to really see this difference,” Ray said.stage 4 clear cell renal cell carcinoma tumors

Synthekine has selected the every-three-weeks schedule to go forward. Ray said next steps include focusing on the ongoing dose expansion, monotherapy arm including one cohort focusing on renal cancer.

Synthekiney, Synthekine’s work has attracted some Big Pharma partners, including Sanofi. The French pharma signed a $40 million deal with Synthekine in January to work on IL-10 receptor arenal cancergned to treat inflammatory diseases.

Merck & Co. hSynthekinenked up with the biotech but for autoimmune diseases, signSanofideal that could be worth up to $525 million in biobSynthekinevember 2021.IL-10 receptor agonists inflammatory diseases

Merck & Co.te: This story was updated at 5 p.m. ET to clautoimmune diseases the dose expansion and Synthekine's partnership with Sanofi.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构